In EDS ansehen

Interleukin-17 and myeloperoxidase levels in patients with non-alcoholic fatty liver disease and effect of disease severity on blood counts and liver enzymes

Gespeichert in:
Bibliographische Detailangaben
Titel: Interleukin-17 and myeloperoxidase levels in patients with non-alcoholic fatty liver disease and effect of disease severity on blood counts and liver enzymes
Autoren: Mamoona Nazir, Ahmer Ijaz, Nayab Imtiaz, Muhammad Yasir Khan, Gulab Fatima Rani
Quelle: Khyber Medical University Journal, Vol 17, Iss 1, Pp 71-6 (2025)
Verlagsinformationen: Khyber Medical University, 2025.
Publikationsjahr: 2025
Bestand: LCC:Medicine
Schlagwörter: interleukin-17, myeloperoxidase, peroxidase, non-alcoholic fatty liver disease, nafld, fatty liver, liver enzymes, complete blood counts, alanine transaminase, aspartate aminotransferases, blood cell count, platelets, Medicine
Beschreibung: Objectives: To compare the circulating levels of interleukin-17 (IL-17) and myeloperoxidase (MPO) in non-alcoholic fatty liver disease (NAFLD) patients and healthy controls, and to assess the impact of disease severity on blood counts and liver enzyme levels, exploring their potential as early markers. Methods: This cross-sectional study was conducted at Hayatabad Medical Complex and Khyber Medical University, Peshawar, Pakistan from January to December 2023 after ethical approval. Using purposive sampling, 20 healthy controls and 60 NAFLD patients (20 each with mild, moderate, and severe disease) aged ≥25 were enrolled. NAFLD was diagnosed via ultrasonography. Blood samples were collected for complete blood counts and liver enzyme assays (ALT and AST), while serum IL-17 and MPO levels were measured by ELISA. NAFLD severity was assessed using FIB-4, APRI, and AST/ALT ratios. Data were analyzed with Prism Graphpad using ANOVA with Dunnett’s tests and Kruskal-Wallis tests, with p ≤ 0.05 considered significant. Results: Controls had a mean age of 32.9±7.0 years, versus 59.3±10.1 years in NAFLD patients. Liver enzymes, severity scores, and the AST/ALT ratio increased significantly with NAFLD severity. IL-17 levels rose from 0.064 ng/ml in controls to 0.133, 0.223, and 0.278 ng/ml in mild, moderate, and severe cases (p
Publikationsart: article
Dateibeschreibung: electronic resource
Sprache: English
ISSN: 2305-2643
2305-2651
Relation: https://www.kmuj.kmu.edu.pk/article/view/23728; https://doaj.org/toc/2305-2643; https://doaj.org/toc/2305-2651
DOI: 10.35845/kmuj.2025.23728
Zugangs-URL: https://doaj.org/article/cf35ceea01554f9d9a1aa8c069bf77d6
Dokumentencode: edsdoj.f35ceea01554f9d9a1aa8c069bf77d6
Datenbank: Directory of Open Access Journals
Beschreibung
Abstract:Objectives: To compare the circulating levels of interleukin-17 (IL-17) and myeloperoxidase (MPO) in non-alcoholic fatty liver disease (NAFLD) patients and healthy controls, and to assess the impact of disease severity on blood counts and liver enzyme levels, exploring their potential as early markers. Methods: This cross-sectional study was conducted at Hayatabad Medical Complex and Khyber Medical University, Peshawar, Pakistan from January to December 2023 after ethical approval. Using purposive sampling, 20 healthy controls and 60 NAFLD patients (20 each with mild, moderate, and severe disease) aged ≥25 were enrolled. NAFLD was diagnosed via ultrasonography. Blood samples were collected for complete blood counts and liver enzyme assays (ALT and AST), while serum IL-17 and MPO levels were measured by ELISA. NAFLD severity was assessed using FIB-4, APRI, and AST/ALT ratios. Data were analyzed with Prism Graphpad using ANOVA with Dunnett’s tests and Kruskal-Wallis tests, with p ≤ 0.05 considered significant. Results: Controls had a mean age of 32.9±7.0 years, versus 59.3±10.1 years in NAFLD patients. Liver enzymes, severity scores, and the AST/ALT ratio increased significantly with NAFLD severity. IL-17 levels rose from 0.064 ng/ml in controls to 0.133, 0.223, and 0.278 ng/ml in mild, moderate, and severe cases (p
ISSN:23052643
23052651
DOI:10.35845/kmuj.2025.23728